Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Psoriasis, Obesity
Interventions: Adipose tissue biopsy (fat biopsy); Procedure
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Allergy;Food, Adherence, Treatment, Child, Only
Interventions: Food Allergy Superheroes Training (FAST) Program, Food Allergy Knowledge Intervention; Behavioral · Other
Lead sponsor: Kent State University; Other
Eligibility: 6 Years to 8 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Kent, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (Insulin Glargine 300 U/ml), Lantus (Insulin Glargine 100 U/ml), Mandated back ground therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 99
States / cities: Little Rock, Arkansas • Concord, California • Escondido, California + 80 more

Conditions: Healthy Subjects
Interventions: ABBV-7828, Placebo for ABBV-7828; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy
Interventions: Loxapine Succinate Capsules 25 mg, Loxitane® Capsules 25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Spirometry test, Levalbuterol; Device · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson's Disease
Interventions: blood draw; Genetic
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: AIS
Interventions: NBP Softgel Capsules, Placebo; Drug
Lead sponsor: CSPC-NBP Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 21
States / cities: Los Angeles, California • Jacksonville, Florida • Des Moines, Iowa + 15 more

Conditions: Healthy
Interventions: Terbinafine HCl 250mg tablets, Lamisil® 250 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 2 Diabetes Mellitus
Interventions: LY3209590, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 31
States / cities: Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 26 more

Conditions: Short Bowel Syndrome
Interventions: Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection; Drug · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteer
Interventions: Treatment A: Naloxone Nasal Spray, Treatment B: Naloxone Nasal Spray, Treatment C: Naloxone HCL Intramuscular (IM) Injection; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Metabolic Syndrome, Pre-Diabetes
Interventions: Time Restricted Eating + Standard of Care, Standard of Care; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy
Interventions: Cilostazol 100 mg tablets, Pletal® 100 mg tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: Zibotentan/Dapagliflozin FDC; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: Olmesartan Medoxomil Tablets 40 mg, Benicar® Tablets 40 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide, Glipizide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Coronary Syndrome
Interventions: vicagrel Capsules, Clopidogrel Tablets; Drug
Lead sponsor: Jiangsu vcare pharmaceutical technology co., LTD; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Kansas City, Missouri

Conditions: Healthy Volunteers
Interventions: GDC-0134 F09 Formulation, GDC-0134 F15 Formulation, GDC-0134 F16 Formulation; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: maltodextrin, super starch; Dietary Supplement
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Obesity
Interventions: Packaging and identification of source; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 0 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Stanford, California

Conditions: Osteoporosis, Osteopenia or Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Risk, Osteoporotic Fractures, Fragility Fracture, Bone Fracture
Interventions: Cortical Bone Mechanics Technology; Diagnostic Test
Lead sponsor: Ohio University; Other
Eligibility: 50 Years to 80 Years · Female only
Enrollment: 394 participants
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 2 more

Conditions: Healthy
Interventions: Glimepiride 4 mg Tablets, AMARYL® 4 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects

The Food Allergy Superheroes Training (FAST) Program

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults

Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg

COPD Assessment and Management Bundle Versus Usual Care

Parkinson's Disease Genetics Database

NBP in Adult Patients With Acute Ischemic Stroke (AIS)

Terbinafine HCl 250 mg Tablet Under Fasting Conditions

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

rHGH and Intestinal Permeability in Intestinal Failure

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

The Influence of Time-Restricted Eating in Patients With Metabolic Syndrome

Cilostazol 100 mg Tablet Formulations Under Fasting Conditions

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

Effect of Exenatide on Liver and Heart Fat and Inflammation

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

Slow Digestible Carbohydrates and Exercise in Adolescents With Type 1 Diabetes

Effects of Advertising on Young Children's Perception of Taste

Assessment of Cortical Bone Mechanics Technology (CBMT) Fracture Discrimination Capability

Glimepiride 4 mg Tablets Under Non-Fasting Conditions